Alzheimer's disease and cholinesterase inhibitors
DOI:
https://doi.org/10.51481/amc.v45i2.96Keywords:
Inhibidores de colinesterasa, enfermedad de Alzheimer, tratamiento, rivastigminaAbstract
Alzheimer's disease has a higher incidence in elderly than inmiddle-aged persons. As the expectancy of life increases,thisdisease becomes more frequent. It is characterized by a pro-gressive loss of cognitive and motor abilities. Finding anadequate treatment has become a scientific challenge in re-cent years,because even though the physiopathology of thisdisease was described many years ago,no treatment wasavailable for a long time. The studies on colinesterase inhi-bitors began since the early 90 ̈s representing these drugs afirst possible cure. In 1993,tacrine,the first colinesterase in-hibitor, was approved for use in patients with Alzheimer 'sdisease. Nowadays we have multiple drugs of this type,somewith excellent results such as rivastigmine. Even though theyare of the same pharmacological class,these drugs are verydifferent in their selectivity,specificity and adverse sideeffects.
Downloads
References
www.ciudadfutura.com/temassalud/articulos/alzheiach.pdf
Farlow RM. Chlolinesterase inhibitors:relating pharmacological pro-perties to clinical profiles. Int J Clin Pract 2002; Suppl 127:1-5.
Zurad E. Nuevos tratamientos de la Enfermedad de Alzheimer:una re-visión. Drug Benedit Trends 2001:1-9.
Makeup R,Sano M. Treatment of Alzheimer's disease. N Engl J Med1999; 341:1671-9
Frolich L. Psychosocial care in Alzheimer's disease:a clinician's pers-pective.Alzheimer Insights 1999; Jan:18-20.
Flórez J. Farmacología humana. España:Editorial Masson,1997:222-224,594-596.
Davies K,Maloney,A. Selective loss of central cholinergic neurons inAlzheimer disease. Lancet 1976; 2:1403-7.
Geula C,Mesulam M-M. Chonigergic systems and related neropatho-logical predilection patterns in Alzheimer Disease. In Terry RD,Katz-man R,Bick KL,Eds. Alzheimer Disease. New York,USA:RavenPress Ltd,1994:263-291.
McKeith I. Dementia with Lewy bodies. Br J Psychiatry 2002; 180:144-147.
Esiri MM,McShane RH. Parkinson's Disease and Dementia. In:EsiriMM,Morris JH,Eds. The neuropathology of dementia. Cambridge,UK:Cambridge University Press,1997; Chapter 6:174-193.
w w w. j ave ri a n a . e d u . c o / fa c u l t a d e s / c i e n c i a s / j a i ro / n e u ro b i o q u i m i c a / n e u-rotransmisores/acetilcolina.htm.
Arendt T. Mecanismos colinérgicos de trastornos del comportamientoen Enfermedad de Alzheimer.Alzheimer Insights 2001; Feb:1-3.
w w w. m e d m ayo r. cl / ap u n t e s / fa rm a c o l ogi a / c o l i n e rgi c o s , % 2 0 a d re n e rgi-cos%20y%20serotoninergicos.htm.
Greig N et al. Butirilcolinesterasa:un nuevo objetivo terapéutico en eltratamiento de la Enfermedad de Alzheimer? Alzheimer Insights 2001;Jun 1-3.
Bryant J et al. Clinical and cost-effectiveness of donepezil,rivastigmi-ne and galantamine for Alzheimer Disease:a rapid and systematicreview. Health Technol Assess 2001; 5:1-137
Doody R et al. Practice Parameter:Managemente of dementia (an evi-dence based review). Reports of the Quality Standards Subcommitteeof the American Academy of Neurology. Neurology 2001; 56:1154-1166.
GrayA. Meeting the economic challenges of Alzheimer's disease:willdrug interventions ease the burden? Alzheimer Insights 2000; May:4-6.
Farlow M et al. A 52-week study of the efficacy of rivastigmime in pa-tients with mild to moderately severeAlzheimer's disease. Eur Neurol2000; 44:234-241.
Mesulam M et al. Widely spread butyrylcolinesterase can hydrolyzeaceticholine in the normal and Alzheimer brain. Neurobiol Dis 2002; 9:88-93.
Lie B et al. Abundant tissue butyrylcolinestyerase and its posible func-tion in the acetylcholinesterase knockout mouse. J Neurochem 2000;75:1320-1331
Roesler M,Retz W,Retz Junginger P,Dennler HJ. Effects of two-yeartreatment with the cholinesterase inhibitor rivastigmine on behavioralsymptoms in Alzheimer s Disease. Behav Neurol 1998; 11:211-216.
Arendt T. Changes in acetylcholinesterase and butyrylcholinesterase inAlzheimer. Neurochem1992; 4:12-17.
Poirier J. Evidence that the clinical effects of cholinesterase inhibitorsare related to potency and targeting of action. Int J Clin Pract 2002;Suppl 127:6-17.
Inglis F. The tolerability and safety of cholinesterase inhibitors in thetreatment of dementia. Int J Clin Pract 2002; Suppl 127; 45-58
Davidsson P et al. Differential Increase in cerebrospinal fluid-acetylco-linesterase after treatment with acetylcolinesterase inhibitors in patientswith Alzheimer Disease. Neurosci Lett 2001; 300:157-160.26. VenneriA et al. Cerebral blood flow and cognitive responses to rivas-tigmine treatment in Alzheimer disease. Neuro Report 2002; 5:23-27.
NordbergA et al. Improved cortical glucose metabolism in Alzheimerwith patients treated with rivastigmine for one year. J Neurol Sc 2001;187:14-18.
Doncel B,Drachman D. Incontinent and troublesome behaviors pre-dict institutionalizations. J Geriatric Psychiat 1992; 3:12-16.
Del Ser T. Dementia with Lewy Bodies. Alzheimer Insights 2001;May:1-3.
Weiser M,Rotmensch H. Co-administration of rivastigmine with ris-peridone in dementia patients with behavioral disturbances. Int. J. Ge-riat. Psychiat 2002; 6:28-32.
Corey-Bloom J,Anad R,Messina J, Veach J, for the ENA-713 B352Study Group. A randomized trial evaluating the efficacy and safety ofENA-731 (rivastigmine tartrate),a new acetylcolinesterase inhibitor,inpatients with mild to moderately severeAlzheimer s Disease. Int J Ge-riatr Psychofarmacol 1998; 1:55-65.
Rosler M et al. Efficacy and safety of rivastigmine in patients with Alz-heimer s Disease:international randomized control trial. BMJ 1999;318:633-638.
Schredl M et al. Donepezil-induced REM sleep augmentation,enhan-ces memory performance in elderly,healthy persons. Exp Gerontol2001; 36:353-361.
Potkin S,Messina J,Graham S. Safety of rivastigmine in Alzheimer sDisease. Neurol 2000; 54:2261-2268.
McIntosh A. Manejo en equipo de la demencia en cuidado primario. Vi-sión del R.U.Alzheimer Insights 2001; 7:8-11
Downloads
Published
Issue
Section
License
Copyright (c) 2008 Acta Médica Costarricense
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
